PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 15, 2020Echocardiography26 citations

Speckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta‐analysis

View Full Paper
KBKirolos BarssoumAAAhmed AltibiDRDevesh Rai

Structured PICO

Does speckle tracking echocardiography detect subclinical myocardial involvement in patients with extra-cardiac sarcoidosis compared to healthy controls?

P
Population
967 patients (from 9 studies) with confirmed extra-cardiac sarcoidosis without cardiac symptoms, and healthy controls.
I
Intervention
Speckle tracking echocardiography (STE) measuring left ventricular global longitudinal strain (LVGLS) or global circumferential strain (GCS)
C
Comparator
Healthy controls
O
Outcome
Left ventricular global longitudinal strain (LVGLS) or global circumferential strain (GCS)surrogate

Speckle tracking echocardiography reveals significantly reduced LVGLS and GCS in patients with extra-cardiac sarcoidosis without cardiac symptoms, suggesting its utility for early screening of cardiac involvement.

Abstract

BACKGROUND: This meta-analysis aims to evaluate the utility of speckle tracking echocardiography (STE) as a tool to evaluate for cardiac sarcoidosis (CS) early in its course. Electrocardiography and echocardiography have limited sensitivity in this role, while advanced imaging modalities such as cardiac magnetic resonance (CMR) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) are limited by cost and availability. METHODS: We compiled English language articles that reported left ventricular global longitudinal strain (LVGLS) or global circumferential strain (GCS) in patients with confirmed extra-cardiac sarcoidosis versus healthy controls. Studies that exclusively included patients with probable or definite CS were excluded. Continuous data were pooled as a standard mean difference (SMD), comparing sarcoidosis group with healthy controls. A random-effect model was adopted in all analyses. Heterogeneity was assessed using Q and I2 statistics. RESULTS: Nine studies were included in our final analysis with an aggregate of 967 patients. LVGLS was significantly lower in the extra-cardiac sarcoidosis group as compared with controls, SMD -3.98, 95% confidence interval (CI): -5.32, -2.64, P < .001, also was significantly lower in patients who suffered major cardiac events (MCE), -3.89, 95% CI -6.14, -1.64, P < .001. GCS was significantly lower in the extra-cardiac sarcoidosis group as compared with controls, SMD: -3.33, 95% CI -4.71, -1.95, P < .001. CONCLUSION: LVGLS and GCS were significantly lower in extra-cardiac sarcoidosis patients despite not exhibiting any cardiac symptoms. LVGLS correlates with MCEs in CS. Further studies are required to investigate the role of STE in the early screening of CS.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Barssoum et al. (2020) studied this question.

synapsesocial.com/papers/6a19737411f0614219d97a63https://doi.org/10.1111/echo.14886
Ask AI
Helpful
Bookmark
Share
View Full Paper